Brief: Oncopeptides: Regulatory Approval To Start Window-Of-Opportunity Study In Glioblastoma
May 19 (Reuters) - Oncopeptides AB ONCO.ST: ONCOPEPTIDES: ONCOPEPTIDES SECURES REGULATORY APPROVAL TO START WINDOW-OF-OPPORTUNITY STUDY IN GLIOBLASTOMA FROM NORWEGIAN AUTHORITIES Source text: ID:nMFN61VGyZ Further company coverage: ONCO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy